Scolaris Content Display Scolaris Content Display

Adjuvant therapy with antidepressants for the management of inflammatory bowel disease

This is not the most recent version

References

Additional references

AMH 2012

Australian Medicines Handbook Pty Ltd. Duloxetine. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd, 2012.

Baumeister 2011

Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD008012.pub3]

Baumeister 2014

Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus: an abridged Cochrane review. Diabetic Medicine 2014;31(7):773‐86.

Bennebroek Evertsz 2012

Bennebroek Evertsz F, Bockting CL, Stokkers PC, Hinnen C, Sanderman R, Sprangers MA. The effectiveness of cognitive behavioral therapy on the quality of life of patients with inflammatory bowel disease: multi‐center design and study protocol (KL!C‐ study). BMC Psychiatry 2012;12:227.

Bernstein 2011

Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M. A prospective population‐based study of triggers of symptomatic flares in IBD. American Journal of Gastroenterology 2011;105(9):1994‐2002.

Brown 2005

Brown ES, Vigil L, Khan DA, Liggin JD, Carmody TJ, Rush AJ. A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study. Biological Psychiatry 2005;58(11):865‐70.

CCA 2015

Crohn's, Colitis Australia. About Crohn's and Colitis. www.crohnsandcolitis.com.au/about‐crohns‐colitis (accessed 13 December 2016).

CCFA 2012

Crohn's and Colitis Foundation of America. About the Epidemiology of IBD. www.ccfa.org/resources/epidemiology.html (accessed 13 December 2016).

D'Haens 2008

D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371(9613):660‐7.

Daghaghzadeh 2015

Daghaghzadeh H, Naji F, Afshar H, Sharbafchi MR, Feizi A, Maroufi M, et al. Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: a double‐blind controlled study. Journal of Research in Medical Sciences 2015;20(6):595‐601.

Deeks 2001

Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: Egger M, Davey SG, Altman DG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context. BMJ Publication Group, 2001.

Deeks 2002

Deeks JJ. Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomes. Statistics in Medicine 2002;21(11):1575‐1600.

Deeks 2011

Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34.

Elbourne 2002

Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9.

Feagan 2007

Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, et al. The effects of infliximab therapy on health‐related quality of life in ulcerative colitis patients. American Journal of Gastroenterology 2007;102(4):794‐802.

Ford 2009

Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta‐analysis. Gut 2009;58(3):367‐78.

Ford 2014

Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta‐analysis. American Journal of Gastroenterology 2014;109(9):1350‐65.

Fuller‐Thomson 2006

Fuller‐Thomson E, Sulman J. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflammatory Bowel Diseases 2006;12(8):697‐707.

Gartlehner 2007

Gartlehner G, Hansen RA, Thieda P, DeVeaugh‐Geiss AM, Gaynes BN, Krebs EE, et al. Comparative Effectiveness of Second‐Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Rockville, MD: Agency for Healthcare Research and Quality, 2007.

Gartlehner 2011

Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux LJ, Van Noord M, et al. Second‐Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. Rockville, MD: Agency for Healthcare Research and Quality, 2011.

Gordon 2013

Gordon A, Mikocka‐Walus A, Grzeskowiak LE, Jayasekara RS. Antidepressants for depression during pregnancy. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD010710]

Guemei 2008

Guemei AA, El Din NM, Baraka AM, El Said Darwish I. Do desipramine [10,11‐dihydro‐5‐[3‐(methylamino) propyl]‐5H‐dibenz[b,f]azepine monohydrochloride] and fluoxetine [N‐methyl‐3‐phenyl‐3‐[4‐(trifluoromethyl)phenoxy]‐propan‐1‐amine] ameliorate the extent of colonic damage induced by acetic acid in rats?. Journal of Pharmacology and Experimental Therapeutics 2008;327(3):846‐50.

Guyatt 2008

Guyatt GH, Oxman AD, Vist GE, Kunz, R, Falck‐Ytter Y, Alonso‐Coello P. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924‐6.

Haapamaki 2013

Haapamaki J, Tanskanen A, Roine RP, Blom M, Turunen U, Mantyla J, et al. Medication use among inflammatory bowel disease patients: excessive consumption of antidepressants and analgesics. Scandinavian Journal of Gastroenterology 2013;48(1):42‐50.

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60.

Higgins 2011

Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.

Knowles 2013

Knowles SR, Monshat K, Castle DJ. The efficacy and methodological challenges of psychotherapy for adults with inflammatory bowel disease: a review. Inflammatory Bowel Diseases 2013;19(12):2704‐15.

Krommydas 2005

Krommydas G, Gourgoulianis KI, Karamitsos K, Krapis K, Kotrotsiou E, Molyvdas PA. Therapeutic value of antidepressants in asthma. Medical Hypotheses 2005;64(5):938‐40.

Loftus 2004

Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126(6):1504‐17.

Maes 2001

Maes M. The immunoregulatory effects of antidepressants. Human Psychopharmacology 2001;16(1):95‐103.

Maunder 2008

Maunder RG, Levenstein S. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. Current Molecular Medicine 2008;8(4):247‐52.

McCombie 2016

McCombie A, Gearry R, Andrews J, Mulder R, Mikocka‐Walus A. Does computerized cognitive behavioral therapy help people with inflammatory bowel disease? A randomized controlled trial. Inflammatory Bowel Diseases 2016;22(1):171‐81.

Mikocka‐Walus 2006

Mikocka‐Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ. Antidepressants and inflammatory bowel disease: a systematic review. Clinical Practice and Epidemiology in Mental Health 2006;2:24.

Mikocka‐Walus 2007

Mikocka‐Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ. "It doesn't do any harm, but patients feel better": a qualitative exploratory study on gastroenterologists' perspectives on the role of antidepressants in inflammatory bowel disease. BMC Gastroenterology 2007;7:38.

Mikocka‐Walus 2009

Mikocka‐Walus A, Clarke D, Gibson P. Can antidepressants influence the course of inflammatory bowel disease (IBD)? The current state of research. European Gastroenterology and Hepatology Review 2009;5(1):48‐53.

Mikocka‐Walus 2012

Mikocka‐Walus AA, Gordon AL, Stewart BJ, Andrews JM. The role of antidepressants in the management of inflammatory bowel disease (IBD): a short report on a clinical case‐note audit. Journal of Psychosomatic Research 2012;72(2):165‐7.

Mikocka‐Walus 2015

Mikocka‐Walus A, Bampton P, Hetzel D, Hughes P, Esterman A, Andrews JM. Cognitive‐behavioural therapy has no effect on disease activity but improves quality of life in subgroups of patients with inflammatory bowel disease: a pilot randomised controlled trial. BMC Gastroenterology 2015;15:54.

Mikocka‐Walus 2016

Mikocka‐Walus A, Pittet V, Rossel JB, von Känel R, Swiss IBD Cohort Study Group. Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2016;14(6):829‐35.

Mikocka‐Walus 2017

Mikocka‐Walus A, Hughes PA, Bampton P, Gordon A, Campaniello MA, Mavrangelos C, et al. Fluoxetine for maintenance of remission and to improve quality of life in patients with Crohn's disease: a pilot randomized placebo‐controlled trial. Journal of Crohn's and Colitis 2017;11(4):509‐14.

Nigro 2001

Nigro G, Angelini G, Grosso SB, Caula G, Sategna‐Guidetti C. Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. Journal of Clinical Gastroenterology 2001;32(1):66‐8.

NIH 2014

National Institutes of Health. Quality Assessment Tool for Case Series Studies. www.nhlbi.nih.gov/health‐pro/guidelines/in‐develop/cardiovascular‐risk‐reduction/tools/case_series (accessed 13 December 2016).

NIH 2016

National Institutes of Health. Quality Assessment Tool for Observational Cohort and Cross‐Sectional Studies. www.nhlbi.nih.gov/health‐pro/guidelines/in‐develop/cardiovascular‐risk‐reduction/tools/cohort (accessed 13 December 2016).

O'Brien 2006

O'Brien SM, Scott LV, Dinan TG. Antidepressant therapy and C‐reactive protein levels. British Journal of Psychiatry 2006;188:449‐52.

RCP 2014

Royal College of Physicians. National audit of inflammatory bowel disease (IBD) service provision. www.rcplondon.ac.uk/projects/outputs/ibd‐audit‐and‐transparency‐data (accessed 13 December 2016).

Ritter 2015

Ritter JM, Flower R, Henderson G, Rang HP. Rang & Dale's Pharmacology. 8th Edition. London: Churchill Livingstone, 2015.

Rocchi 2012

Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, et al. Inflammatory bowel disease: a Canadian burden of illness review. Canadian Journal of Gastroenterology 2012;26(11):811‐7.

Ruepert 2011

Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD003460.pub3]

Shorter 2009

Shorter E. The history of lithium therapy. Bipolar Disorders 2009;11(Suppl 2):4‐9.

Sterne 2011

Sterne JA, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Szuster‐Ciesielska 2003

Szuster‐Ciesielska A, Tustanowska‐Stachura A, Slotwinska M, Marmurowska‐Michalowska H, Kandefer‐Szerszen M. In vitro immunoregulatory effects of antidepressants in healthy volunteers. Polish Journal of Pharmacology 2003;55(3):353‐62.

Timmer 2011

Timmer A, Preiss JC, Motschall E, Rucker G, Jantschek G, Moser G. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD006913.pub2]

Van Langenberg 2010

van Langenberg DR, Lange K, Hetzel DJ, Holtmann GJ, Andrews JM. Adverse clinical phenotype in inflammatory bowel disease: a cross sectional study identifying factors potentially amenable to change. Journal of Gastroenterology and Hepatology 2010;25(7):1250‐8.

Varghese 2006

Varghese AK, Verdu EF, Bercik P, Khan WI, Blennerhassett PA, Szechtman H, et al. Antidepressants attenuate increased susceptibility to colitis in a murine model of depression. Gastroenterology 2006;130(6):1743‐53.

Verbeke 2000

Verbeke M, Molenberghs G. Linear Mixed Models for Longitudinal Data. 2nd Edition. New York: Springer, 2000.

Walker 2008

Walker JR, Ediger JP, Graff LA, Greenfeld JM, Clara I, Lix L, et al. The Manitoba IBD cohort study: a population‐based study of the prevalence of lifetime and 12‐month anxiety and mood disorders. American Journal of Gastroenterology 2008;103(8):1989‐97.

Wells 2000

Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle scale for assessing the quality of nonrandomised studies in meta‐analyses. www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 13 December 2016).

Williams 2000

Williams JW, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Annals of Internal Medicine 2000;132(9):743‐56.